NSCL-J 6-6 ►新增参考文献 40:Solomon BJ, Drilon A, Lin JJ, et al. Repotrectinib in patients with NTRK fusion-positive advanced solid tumors, including non-small cell lung cancer: update from the phase 1/2 TRIDENT-1 trial....
参考文献: [1] Liu P, Wang Y, Li X. Targeting the untargetable KRAS in cancer therapy. Acta Pharm Sin B 2019;9:871-879. [2] Janne PA, et al. Adagrasib in non-small-cell lung cancer harboring a KRAS G12C mutation. N Engl J Med 2022;387:120-131. 为了能更好地为大家提供更有...
[5]LUMAKRAS® (SOTORASIB) CODEBREAK 100 STUDY SHOWS TWO-YEAR OVERALL SURVIVAL OF 32.5% IN PATIENTS WITH KRAS G12C-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER| Amgen https://www.amgen.com/newsroom/press-releases/2022/04/...
►新增参考文献 40:Solomon BJ, Drilon A, Lin JJ, et al. Repotrectinib in patients with NTRK fusion-positive advanced solid tumors, including non-small cell lung cancer: update from the phase 1/2 TRIDENT-1 trial. Ann Oncol. 2023;34:S787-S788. 知识拓展 根据TRIDENT-1Ⅰ期试验结果,瑞普...
[1]NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines®)Non-Small Cell Lung Cancer.Version 1.2023. [2]Burnett H,Emich H,Carroll C,et al.Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer:A systematic literature review[J].PLoS One,...
靶向治疗及免疫治疗在非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗中发挥了重要的作用,分子分型是NSCLC实施治疗的前提。检测的标准化可提升检测结果的准确性,使患者更大程度上获益。随着分子检测技…
[4] O'Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 2022;23:1274-1286. ...
靶向治疗及免疫治疗在非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗中发挥了重要的作用,分子分型是NSCLC实施治疗的前提。检测的标准化可提升检测结果的准确性,使患者更大程度上获益。随着分子检测技术的发展和肿瘤相关通路研究的深入,越来越多的与NSCLC治疗相关的基因及位点被发现。
[4] O'Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol 2022;23:1274-1286....
[1].NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines®)Non-Small Cell Lung Cancer.Version 1.2023. [2].NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines®)Non-Small Cell Lung Cancer.Version 1-6.2022. 医生站网页版上线啦!